Compare Stocks: CGON, INSM, EXEL, and ASND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$243.37 +0.2%	$243.04	$188.07 ▼ $282.15	$15.16B	0.38	746,147 shs	575,459 shs
CGON CG Oncology	$61.71 -1.3%	$70.83	$35.80 ▼ $80.97	$5.54B	0.28	987,401 shs	1.06 million shs
EXEL Exelixis	$64.53 -1.2%	$58.19	$36.00 ▼ $65.50	$15.99B	0.47	2.27 million shs	2.07 million shs
INSM Insmed	$93.39 -1.8%	$115.25	$90.39 ▼ $212.75	$20.76B	0.83	2.97 million shs	3.41 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+0.16%	+8.04%	+9.07%	-4.13%	+20.06%
CGON CG Oncology	-1.33%	+3.11%	-15.88%	-10.98%	+47.24%
EXEL Exelixis	-1.19%	+3.70%	+13.75%	+16.54%	+78.85%
INSM Insmed	-1.76%	-2.99%	-21.08%	-12.65%	-41.78%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$243.37 +0.2%	$243.04	$188.07 ▼ $282.15	$15.16B	0.38	746,147 shs	575,459 shs
CGON CG Oncology	$61.71 -1.3%	$70.83	$35.80 ▼ $80.97	$5.54B	0.28	987,401 shs	1.06 million shs
EXEL Exelixis	$64.53 -1.2%	$58.19	$36.00 ▼ $65.50	$15.99B	0.47	2.27 million shs	2.07 million shs
INSM Insmed	$93.39 -1.8%	$115.25	$90.39 ▼ $212.75	$20.76B	0.83	2.97 million shs	3.41 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+0.16%	+8.04%	+9.07%	-4.13%	+20.06%
CGON CG Oncology	-1.33%	+3.11%	-15.88%	-10.98%	+47.24%
EXEL Exelixis	-1.19%	+3.70%	+13.75%	+16.54%	+78.85%
INSM Insmed	-1.76%	-2.99%	-21.08%	-12.65%	-41.78%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$309.26	27.08% Upside
CGON CG Oncology	2.70	Moderate Buy	$87.50	41.79% Upside
EXEL Exelixis	2.35	Hold	$51.50	-20.19% Downside
INSM Insmed	2.92	Moderate Buy	$198.91	112.99% Upside

Current Analyst Ratings Breakdown

Latest CGON, INSM, EXEL, and ASND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$218.00 ➝ $213.00
10/20/2026	INSM Insmed	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$173.00
10/19/2026	EXEL Exelixis	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/19/2026	EXEL Exelixis	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Market Outperform	$55.00 ➝ $65.00
10/15/2026	CGON CG Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	INSM Insmed	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$307.00 ➝ $269.00
10/13/2026	ASND Ascendis Pharma A/S	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold (C)
10/12/2026	INSM Insmed	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$207.00
10/12/2026	INSM Insmed	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Peer Perform
10/12/2026	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$220.00

(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	18.64	N/A	N/A	($2.97) per share	-81.94
CGON CG Oncology	$4.04M	1,353.95	N/A	N/A	$9.33 per share	6.61
EXEL Exelixis	$2.44B	6.56	$2.99 per share	21.58	$8.06 per share	8.01
INSM Insmed	$606.42M	33.63	N/A	N/A	$3.46 per share	26.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	18.88	27.34	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	20.29	17.39	1.83	35.33%	42.17%	31.76%	10/29/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	100.42	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)

Latest CGON, INSM, EXEL, and ASND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	CGON CG Oncology	-$0.8341	N/A	N/A	N/A	$0.55 million	N/A
11/11/2026	Q3 2026	ASND Ascendis Pharma A/S	$0.9130	N/A	N/A	N/A	$412.06 million	N/A
10/29/2026	Q3 2026	EXEL Exelixis	$0.8870	N/A	N/A	N/A	$646.51 million	N/A
10/29/2026	Q3 2026	INSM Insmed	-$0.3879	N/A	N/A	N/A	$499.06 million	N/A
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
CGON CG Oncology	N/A	22.22	22.20
EXEL Exelixis	N/A	3.46	3.38
INSM Insmed	0.74	3.72	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
CGON CG Oncology	26.56%
EXEL Exelixis	85.27%
INSM Insmed	N/A

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
CGON CG Oncology	4.80%
EXEL Exelixis	2.60%
INSM Insmed	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable

CGON, INSM, EXEL, and ASND Headlines

Recent News About These Companies

Ty Pennington Talks HGTV's 'Rock The Block' & Mom’s Chronic Lung Condition (Exclusive)

October 23 at 11:08 PM | msn.com

Brensocatib Launches in Japan for Non-CF Bronchiectasis

October 22 at 7:59 PM | ajmc.comA

Insmed (INSM) Gets a Buy from Roth MKM

October 22 at 2:59 PM | theglobeandmail.com

Insmed names former Sanofi and Novartis CEO Hudson and biopharma exec Koppikar to board

October 22 at 2:59 PM | roi-nj.comR

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

October 22 at 11:02 AM | zacks.com

The Escalator: CSL, Insmed, Amgen and more

October 22 at 9:58 AM | mmm-online.comM

Insmed (INSM) Projected to Post Quarterly Earnings on Thursday

October 22 at 2:25 AM | marketbeat.com

Paul Hudson joins Insmed board with immediate effect

October 21 at 6:14 PM | el-balad.comE

Extension Studies in TPIP Show Promise in PAH, PH-ILD

October 21 at 1:11 PM | ajmc.comA

Product launch round-up: 21 October 2026

October 21 at 7:47 AM | thepharmaletter.comT

[MFN Part 5] Why Cheap Japan Was Chosen First

October 21 at 7:47 AM | note.comN

Insmed introduces Brinsupri tablets 25 mg to treat non-cystic fibrosis bronchiectasis in Japan

October 21 at 7:47 AM | pharmabiz.comP

Insmed Appoints Two New Directors to Its Board

October 20, 2026 | prnewswire.com

Insmed, Inc. (NASDAQ:INSM) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

October 20, 2026 | americanbankingnews.com

Insmed, Inc. (INSM) - What Are Brokerages Thinking About This Stock?

October 20, 2026 | marketbeat.com

Insmed Incorporated Launches BRINSUPRI Tablets 25 Mg For The Treatment Of Non-Cystic Fibrosis Bronchiectasis In Japan

October 19, 2026 | marketscreener.comM

Insmed Launches Brinsupri Tablet in Japan for Non-Cystic Fibrosis Bronchiectasis

October 19, 2026 | finance.yahoo.com

Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

October 19, 2026 | prnewswire.com

Wells Fargo keeps USD 169.00 target for Insmed stock

October 17, 2026 | ad-hoc-news.deA

1,048,518 Insmed, Inc. $INSM Shares Bought by Assenagon Asset Management S.A.

October 16, 2026 | marketbeat.com

HC Wainwright Issues Optimistic Forecast for Insmed Earnings

October 16, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CGON, INSM, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$243.37 +0.38 (+0.16%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$244.60 +1.23 (+0.50%)

As of 10/23/2026 07:30 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

CG Oncology NASDAQ:CGON

$61.71 -0.83 (-1.33%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$61.74 +0.03 (+0.05%)

As of 10/23/2026 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Exelixis NASDAQ:EXEL

$64.53 -0.78 (-1.19%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$63.63 -0.90 (-1.40%)

As of 10/23/2026 07:57 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Insmed NASDAQ:INSM

$93.39 -1.67 (-1.76%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$93.82 +0.43 (+0.46%)

As of 10/23/2026 07:57 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGON, INSM, EXEL, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGON, INSM, EXEL, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGON, INSM, EXEL, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CGON, INSM, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

CG Oncology NASDAQ:CGON

Exelixis NASDAQ:EXEL

Insmed NASDAQ:INSM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGON, INSM, EXEL, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGON, INSM, EXEL, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGON, INSM, EXEL, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CGON, INSM, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

CG Oncology NASDAQ:CGON

Exelixis NASDAQ:EXEL

Insmed NASDAQ:INSM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools